Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug and medical device maker Abbott Laboratories has withdrawn its US biologics license application (BLA) and European marketing authorization application (MAA) for briakinumab (ABT-874).
Subscribe to our email newsletter
Briakinumab is an investigational anti-IL-12/23 monoclonal antibody for the treatment of psoriasis.
In a filing with the Securities and Exchange Commission, the company said following feedback from regulatory authorities indicating the need for further analysis and the potential for additional studies, Abbott plans to evaluate next steps for briakinumab, including resubmission at a later date.